These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 10147441)

  • 1. Enalapril: a review of quality-of-life and pharmacoeconomic aspects of its use in heart failure and mild to moderate hypertension.
    Wilde MI; Bryson HM; Goa KL
    Pharmacoeconomics; 1994 Aug; 6(2):155-82. PubMed ID: 10147441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality of life among 5,025 patients with left ventricular dysfunction randomized between placebo and enalapril: the Studies of Left Ventricular Dysfunction. The SOLVD Investigators.
    Rogers WJ; Johnstone DE; Yusuf S; Weiner DH; Gallagher P; Bittner VA; Ahn S; Schron E; Shumaker SA; Sheffield LT
    J Am Coll Cardiol; 1994 Feb; 23(2):393-400. PubMed ID: 8294693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Costs and effectiveness of angiotensin converting enzyme inhibition in patients with congestive heart failure.
    Paul SD; Kuntz KM; Eagle KA; Weinstein MC
    Arch Intern Med; 1994 May; 154(10):1143-9. PubMed ID: 8185426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II. The V-HeFT VA Cooperative Studies Group.
    Francis GS; Cohn JN; Johnson G; Rector TS; Goldman S; Simon A
    Circulation; 1993 Jun; 87(6 Suppl):VI40-8. PubMed ID: 8500238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of enalapril, hydralazine plus isosorbide dinitrate, and prazosin on hospitalization in patients with chronic congestive heart failure. The V-HeFT VA Cooperative Studies Group.
    Loeb HS; Johnson G; Henrick A; Smith R; Wilson J; Cremo R; Cohn JN
    Circulation; 1993 Jun; 87(6 Suppl):VI78-87. PubMed ID: 8500244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Costs and effects of enalapril therapy in patients with symptomatic heart failure: an economic analysis of the Studies of Left Ventricular Dysfunction (SOLVD) Treatment Trial.
    Glick H; Cook J; Kinosian B; Pitt B; Bourassa MG; Pouleur H; Gerth W
    J Card Fail; 1995 Dec; 1(5):371-80. PubMed ID: 12836712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cost effectiveness of ACE inhibition in therapy of chronic heart failure in Switzerland: evaluation based on the SOLVD study].
    Szucs TD; Goedde M; Berger K; Kiowski W
    Schweiz Med Wochenschr; 1997 Jul; 127(29-30):1234-41. PubMed ID: 9333933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of prerandomization (baseline) variables on mortality and on the reduction of mortality by enalapril. Veterans Affairs Cooperative Study on Vasodilator Therapy of Heart Failure (V-HeFT II). V-HeFT VA Cooperative Studies Group.
    Johnson G; Carson P; Francis GS; Cohn JN
    Circulation; 1993 Jun; 87(6 Suppl):VI32-9. PubMed ID: 8500237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The benefits of early combination treatment of carvedilol and an ACE-inhibitor in mild heart failure and left ventricular systolic dysfunction. The carvedilol and ACE-inhibitor remodelling mild heart failure evaluation trial (CARMEN).
    Remme WJ; Riegger G; Hildebrandt P; Komajda M; Jaarsma W; Bobbio M; Soler-Soler J; Scherhag A; Lutiger B; Rydén L
    Cardiovasc Drugs Ther; 2004 Jan; 18(1):57-66. PubMed ID: 15115904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hydralazine and isosorbide dinitrate combination improves exercise tolerance in heart failure. Results from V-HeFT I and V-HeFT II. The V-HeFT VA Cooperative Studies Group.
    Ziesche S; Cobb FR; Cohn JN; Johnson G; Tristani F
    Circulation; 1993 Jun; 87(6 Suppl):VI56-64. PubMed ID: 8500241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lessons from recent randomized controlled trials for the management of congestive heart failure.
    Riegger GA
    Am J Cardiol; 1993 Jun; 71(17):38E-40E. PubMed ID: 8328366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enalapril decreases prevalence of ventricular tachycardia in patients with chronic congestive heart failure. The V-HeFT II VA Cooperative Studies Group.
    Fletcher RD; Cintron GB; Johnson G; Orndorff J; Carson P; Cohn JN
    Circulation; 1993 Jun; 87(6 Suppl):VI49-55. PubMed ID: 8500239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation by patients with heart failure of the effects of enalapril compared with hydralazine plus isosorbide dinitrate on quality of life. V-HeFT II. The V-HeFT VA Cooperative Studies Group.
    Rector TS; Johnson G; Dunkman WB; Daniels G; Farrell L; Henrick A; Smith B; Cohn JN
    Circulation; 1993 Jun; 87(6 Suppl):VI71-7. PubMed ID: 8500243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Captopril. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.
    Brogden RN; Todd PA; Sorkin EM
    Drugs; 1988 Nov; 36(5):540-600. PubMed ID: 3063499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Congestive heart failure: what should be the initial therapy and why?
    Chatterjee K
    Am J Cardiovasc Drugs; 2002; 2(1):1-6. PubMed ID: 14727993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A cost-effectiveness analysis of enalapril maleate in the management of congestive heart failure in Australia.
    Butler JR; Fletcher PJ
    Aust N Z J Med; 1996 Feb; 26(1):89-95. PubMed ID: 8775534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cost-effectiveness analysis of the treatment with enalapril of chronic heart failure in Spain].
    Antoñanzas Villar F; Antón Botella F; Echevarría Echarri L
    Gac Sanit; 1996; 10(54):135-42. PubMed ID: 8991882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Hypotensive effectiveness of therapy combined enalapril and nitrendipine and influence on the quality of life].
    Bryl W; Cymerys M; Kujawska-Luczak M; Pupek-Musialik D
    Pol Merkur Lekarski; 2005 Mar; 18(105):287-90. PubMed ID: 15997634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cost and cardioprotective effects of enalapril in hypertensive patients with left ventricular dysfunction.
    Cook JR; Glick HA; Gerth W; Kinosian B; Kostis JB
    Am J Hypertens; 1998 Dec; 11(12):1433-41. PubMed ID: 9880125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.